Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
Christopher C DvorakPrakash SatwaniElliot StieglitzMitchell S CairoHa DangQinglin PeiYun GaoDonna WallTali MazorAdam B OlshenJoel S ParkerSamir KahwashBetsy HirschSusana RaimondiNeil PatelMicah SkeensTodd CooperParinda A MehtaStephan A GruppMignon L LohPublished in: Pediatric blood & cancer (2018)
The regimen of Bu-Flu is inadequate to provide disease control in patients with JMML who present to HCT with large burdens of disease. Advances in molecular testing may allow better characterization of biologic risk, pre-HCT responses to chemotherapy, and post-HCT management.